Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can magnetic pulses to the brain quiet nerve pain?

NCT ID NCT07805057

Symptom relief Sponsor: Maastricht University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

Small fiber neuropathy damages tiny nerve fibers, causing severe pain that often resists standard painkillers. This trial tests whether repetitive transcranial magnetic stimulation (rTMS), a non-invasive technique that sends magnetic pulses to specific brain regions, can reduce that pain. About 124 adults with skin-biopsy-confirmed small fiber neuropathy and moderate to severe pain will receive either real rTMS or a sham version over six weeks. Researchers will compare the proportion of responders in each group, defined as at least a 1-point drop on a 0 to 10 pain scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Repetitive transcranial magnetic stimulation (rTMS), a non-invasive technique that delivers magnetic pulses to specific brain regions to reduce pain
What this could lead to
If rTMS eases pain in small fiber neuropathy, it could offer a new, non-drug option for people who get little relief from current pain medications.
What could go wrong
This is an early test in one condition, and pain relief from rTMS may be temporary. The sham comparison will show whether any benefit is real or a placebo effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 124 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older. * Skin-biopsy proven idiopathic SFN. * Pain intensity (maximum pain) rated ≥5 on the PI-NRS, that must have existed for at least 12 weeks before the study. * Written informed consent. Exclusion Criteria: * Signs of large nerve fiber dysfunction (i.e., weakness, loss of vibration sense, hyporeflexia or areflexia, abnormal nerve conduction studies). * Identifiable underlying cause of SFN (diabetes, SCN9A/SCN10A/SCN11A mutations, hypothyroidism, vitamin B12 deficiency, monoclonal gammopathy, alcohol abuse (more than 5 IU/day), malignancies, or drugs that cause neuropathy). * Implanted ferromagnetic devices or other magnetic-sensitive metal implants close to the magnetic coil. * History of epilepsy. * Using pain medication that has changed in the 30 days prior to randomization. * Pregnancy. * Mentally challenged subjects unable to give independent informed consent. * Clinically significant or unstable psychiatric disorder including major depression, (history of) substance abuse and other major disorders in accordance with DSM-V,

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small fiber neuropathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia primary erythermalgia Small Fiber Neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small fiber neuropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Maastricht University Medical Centre +

    Maastricht, Limburg, 6229 HX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.